Potential for Developing a SARS-CoV Receptor Binding Domain (RBD) Recombinant Protein as a Heterologous Human Vaccine against Coronavirus Infectious Disease (COVID)-19

Wen-Hsiang Chen; Peter J. Hotez; Maria Elena Bottazzi

Preprint

Brief Report

Potential for Developing a SARS-CoV Receptor Binding Domain (RBD) Recombinant Protein as a Heterologous Human Vaccine against Coronavirus Infectious Disease (COVID)-19

This version is not peer-reviewed.

This version is not peer-reviewed.

Altmetrics

Downloads

1124

Views

1865

Comments

Submitted:

02 March 2020

Posted:

04 March 2020

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract

Keywords:

Subject:

Medicine and Pharmacology - Pulmonary and Respiratory Medicine

This preprints belongs to the Collection

Preprints on COVID-19 and SARS-CoV-2

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Alerts

MDPI Initiatives

Important Links

Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.

Disclaimer

Potential for Developing a SARS-CoV Receptor Binding Domain (RBD) Recombinant Protein as a Heterologous Human Vaccine against Coronavirus Infectious Disease (COVID)-19

Abstract

Keywords:

Subject:

MDPI Initiatives

Important Links

Subscribe